The histone methyltransferase DOT1L: Regulatory functions and a cancer therapy target

American Journal of Cancer Research

Volumn 5, Issue 9, 2015, Pages 2823-2837

  Wong, Matthew ^a   Polly, Patsie ^b   Liu, Tao ^a,b  

^a CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

DOT1L; DOT1L inhibitors; Gene transcription; Histone methylation; Mixed lineage leukemia

Indexed keywords

1 [3 [[5 (4 AMINO 5 BROMO 7H PYRROLO[2,3 D]PYRIMIDIN 7 YL) 3,4 DIHYDROXYTETRAHYDRO 2 FURFURYL](ISOPROPYL)AMINO]PROPYL] 3 (4 TERT BUTYLPHENYL)UREA; ANTINEOPLASTIC AGENT; EPZ 004777; HISTONE DEMETHYLASE; HISTONE METHYLTRANSFERASE; PINOMETOSTAT; PROTEIN DOT1L; SYC 522; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; DNA DAMAGE; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; EPIGENETICS; HISTONE METHYLATION; HUMAN; LEUKEMIA; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN FUNCTION;

EID: 85006184635     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (113)

1. Strahl B, Allis CD. The language of covalent histone modifications. Nature 2000; 403: 41-45.
2. Parbin S, Kar S, Shilpi A, Sengupta D, Deb M, Rath SK, Patra SK. Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer. J Histochem Cytochem 2014; 62: 11-33.
3. Leung K, Cheng VW, Mok SW, Tsui SK. The Involvement of DNA Methylation and Histone Modification on the Epigenetic Regulation of Embryonic Stem cells and Induced Pluripotent Stem Cells. Curr Stem Cell Res Ther 2014; 9: 388-95.
4. Pérez-Cadahía B, Drobic B, Khan P, Shivashankar CC, Davie JR. Current understanding and importance of histone phosphorylation in regulating chromatin biology. Curr Opin Drug Discov Dev 2010; 13: 613-622.
5. Cao J, Yan Q. Histone ubiquitination and deubiquitination in transcription, DNA damage response, and cancer. Front Oncol 2012; 2: 26.
6. Allfrey VG, Faulkner R, Mirsky AE. Aceylation and Methylation of Histones and their possible role in the Regulation of RNA. Proc Natl Acad Sci U S A 1964; 51: 786-794.
7. Murray K. The occurrence of e-N-methyl lysine in histones. Biochemistry 1964; 3: 10-15.
8. Byvoet P, Shepherd GR, Hardin JM, Noland BJ. The distribution and turnover of labelled methyl groups in histone fractions of cultured mammalian cells. Arch Biochem Biophys 1972; 148: 558-567.
9. Zee B, Levin RS, Xu B, LeRoy G, Wingreen NS, Garcia BA. In vivo residue-specific histone methylation dynamics. J Biol Chem 2010; 285: 3341-3350.
10. Young N, Dimaggio PA, Garcia BA. The significance, development and progress of highthroughput combinatorial histone code analysis. Cell Mol Life Sci 2010; 67: 3983-4000.
11. Zhang YR, Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 2001; 15: 2343-2360.
12. Greer E, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet 2012; 13: 343-357.
13. Noma K, Allis CD, Grewal SI. Transitions in distinct histone H3 methylation patterns at the heterochromatin domain boundaries. Science 2001; 293: 1150-1155.
14. Bernstein BE, Humphrey EL, Erlich RL, Schneider R, Bouman P, Liu JS, Kouzarides T, Schreiber SL. Methylation of histone H3 Lys4 in coding regions of active genes. Proc Natl Acad Sci U S A 2002; 99: 8695-8700.
15. Bannister A, Schneider R, Myers FA, Thorne AW, Crane-Robinson C, Kouzarides T. Spatial distribution of di-and tri-methyl lysine 36 of histone H3 at active genes. J Biol Chem 2005; 280: 17732-17736.
16. Mohan M, Herz HM, Takahashi YH, Lin C, Lai KC, Zhang Y, Washburn MP, Florens L, Shilatifard A. Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev 2010; 24: 574-589.
17. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. Highresolution profiling of histone methylations in the human genome. Cell 2007; 129: 823-837.
18. Snowden A, Gregory PD, Case CC, Pabo CO. Gene-specific targeting of H3K9 methylation is sufficient for initiating repression in vivo. Curr Biol 2002; 12: 2159-2166.
19. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, and Zhang Y. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 2002; 298: 1039-43.
20. Nishioka K, Rice JC, Sarma K, Erdjument-Bromage H, Werner J, Wang Y, Chuikov S, Valenzuela P, Tempst P, Steward R, Lis JT, Allis CD, Reinberg D. PR-Set7 is a nucleosome-specific methyltransferase that modifies lysine 20 of histone H4 and is associated with silent chromatin. Mol Cell 2002; 9: 1201-1213.
21. Dillon S, Zhang X, Trievel RC, Cheng X. The SETdomain protein superfamily: protein lysine methyltransferases. Genome Biol 2005; 6: 227.
22. Nishioka K, Chuikov S, Sarma K, Erdjument-Bromage H, Allis CD, Tempst P, Reinberg D. Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. Genes Dev 2002; 16: 479-489.
23. Wang H, Cao R, Xia L, Erdjument-Bromage H, Borchers C, Tempst P, Zhang Y. Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase. Mol Cell 2001; 8: 1207-1217.
24. Schultz D, Ayyanathan K, Negorev D, Maul GG, Rauscher FJ 3rd. SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zincfinger proteins. Genes Dev 2002; 16: 919-932.
25. Hua K, Wang MY, Chen MW, Wei LH, Chen CK, Ko CH, Jeng YM, Sung PL, Jan YH, Hsiao M, Kuo ML, Yen ML. The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis. Mol Cancer 2014; 13: 189.
26. Bae W, Hennighausen L. Canonical and noncanonical roles of the histone methyltransferase EZH2 in mammary development and cancer. Mol Cell Endocrinol 2014; 382: 593-597.
27. Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, Xu H, Cato L, Thornton JE, Gregory RI, Morrissey C, Vessella RL, Montironi R, Magi-Galluzzi C, Kantoff PW, Balk SP, Liu XS, Brown M. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 2012; 338: 1465-1469.
28. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003; 100: 11606-11611.
29. Majer C, Jin L, Scott MP, Knutson SK, Kuntz KW, Keilhack H, Smith JJ, Moyer MP, Richon VM, Copeland RA, Wigle TJ. A687V EZH2 is a gain-of-function mutation found in lymphoma patients. FEBS Lett 2012; 586: 3448-3451.
30. Sneeringer C, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM, Copeland RA. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A 2010; 107: 20980-20985.
31. Wigle T, Knutson SK, Jin L, Kuntz KW, Pollock RM, Richon VM, Copeland RA, Scott MP. The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states. FEBS Lett 2011; 585: 3011-3014.
32. Konze K, Ma A, Li F, Barsyte-Lovejoy D, Parton T, Macnevin CJ, Liu F, Gao C, Huang XP, Kuznetsova E, Rougie M, Jiang A, Pattenden SG, Norris JL, James LI, Roth BL, Brown PJ, Frye SV, Arrowsmith CH, Hahn KM, Wang GG, Vedadi M, Jin J. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chem Biol 2013; 8: 1324-1334.
33. McCabe M, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A 3rd, Diaz E, LaFrance LV, Mellinger M, Duquenne C, Tian X, Kruger RG, McHugh CF, Brandt M, Miller WH, Dhanak D, Verma SK, Tummino PJ, Creasy CL. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012; 492: 108-112.
34. Knutson S, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, Sacks, JD, Raimondi A, Majer CR, Song J, Scott MP, Jin L, Smith JJ, Olhava EJ, Chesworth R, Moyer MP, Richon VM, Copeland RA, Keilhack H, Pollock RM, Kuntz KW. A Selective Inhibitor of EZH2 Blocks H3K27 Methylation and Kills Mutant Lymphoma Cells. Nature Chem Biol 2012; 8: 890-896.
35. Højfeldt J, Agger K, Helin K. Histone lysine demethylases as targets for anticancer therapy. Nat Rev Drug Discov 2013; 12: 917-930.
36. Allis C, Berger SL, Cote J, Dent S, Jenuwien T, Kouzarides T, Pillus L, Reinberg D, Shi Y, Shiekhattar R, Shilatifard A, Workman J, Zhang Y. New nomenclature for chromatin-modifying enzymes. Cell 2007; 131: 633-636.
37. Yamane K, Toumazou C, Tsukada Y, Erdjument-Bromage H, Tempst P, Wong J, Zhang Y. JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell 2006; 125: 483-495.
38. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y. Histone demethylation mediated by the nuclear amine oxidase homologue LSD1. Cell 2004; 119: 941-53.
39. Forneris F, Binda C, Vanoni MA, Mattevi A, Battaglioli E. Histone demethylation catalysed by LSD1 is a flavin-dependent oxidative process. FEBS Lett 2005; 579: 2203-2207.
40. Forneris F, Binda C, Vanoni MA, Battaglioli E, Mattevi A. Human histone demethylase LSD1 reads the histone code. J Biol Chem 2005; 280: 41360-41365.
41. Forneris F, Binda C, Dall'Aglio A, Fraaije MW, Battaglioli E, Mattevi A. A highly specific mechanism of histone H3-K4 recognition by histone demethylase LSD1. J Biol Chem 2006; 281: 35289-35295.
42. Kooistra S, Helin K. Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol 2012; 13: 297-311.
43. McDonough M, Loenarz C, Chowdhury R, Clifton IJ & Schofield CJ. Structural studies on human 2-oxoglutarate dependent oxygenases. Curr Opin Struc Biol 2010; 20: 659-672.
44. Singer M, Kahana A, Wolf AJ, Meisinger LL, Peterson SE, Goggin C, Mahowald M, Gottschling DE. Identification of high-copy disruptors of telomeric silencing in Saccharomyces cerevisiae. Genetics 1998; 150: 613-632.
45. List O, Togawa T, Tsuda M, Matsuo T, Elard L, Aigaki T. Overexpression of grappa encoding a histone methyltransferase enhances stress resistance in Drosophila. Hereditas 2009; 146: 19-28.
46. Jansen C, Hake SB, Lowell JE, Cross GA. Selective di-or trimethylation of histone H3 lysine 76 by two DOT1 homologs is important for cell cycle regulation in Trypanosoma brucei. Mol Cell 2006; 23: 497-507.
47. Jones B, Su H, Bhat A, Lei H, Bajko J, Hevi S, Baltus GA, Kadam S, Zhai H, Valdez R, Gonzalo S, Zhang Y, Li E, Chen T. The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure. PLoS Genet 2008; 4: e1000190.
48. Min J, Feng Q, Li Z, Zhang Y, Xu RM. Structure of the catalytic domain of human DOT1L, a non-SET domain nucleosomal histone methyltransferase. Cell 2003; 112: 711-723.
49. Feng Q, Wang H, Ng HH, Erdjument-Bromage H, Tempst P, Struhl K, Zhang Y. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol 2002; 12: 1052-1058.
50. Sawada K, Yang Z, Horton JR, Collins RE, Zhang X, Cheng X. Structure of the conserved core of the yeast Dot1p, a nucleosomal histone H3 lysine 79 methyltransferase. J Biol Chem 2004; 279: 43296-43306.
51. Daigle S, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, Johnston LD, Scott MP, Smith JJ, Xiao Y, Jin L, Kuntz KW, Chesworth R, Moyer MP, Bernt KM, Tseng JC, Kung AL, Armstrong SA, Copeland RA, Richon VM and Pollock RM. Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor. Cancer Cell 2011; 20: 53-65.
52. Daigle S, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin PA, Allain CJ, Klaus CR, Raimondi A, Scott MP, Waters NJ, Chesworth R, Moyer MP, Copeland RA, Richon VM, Pollock RM. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 2013; 122: 1017-1025.
53. Anglin J, Song Y. A Medicinal Chemistry Perspective for Targeting Histone H3 Lysine-79 Methyltransferase DOT1L. J Med Chem 2013; 56: 8972-8983.
54. Zhang K, Siino JS, Jones PR, Yau PM, Bradbury EM. A mass spectrometric "Western blot" to evaluate the correlations between histone methylation and histone acetylation. Proteomics 2004; 4: 3765-3775.
55. Schübeler D, MacAlpine DM, Scalzo D, Wirbelauer C, Kooperberg C, van Leeuwen F, Gottschling DE, O'Neill LP, Turner BM, Delrow J, Bell SP, Groudine M. The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev 2004; 18: 1263-1271.
56. Morillon A, Karabetsou N, Nair A, Mellor J. Dynamic lysine methylation on histone H3 defines the regulatory phase of gene transcription. J Mol Cell 2005; 18: 723-734.
57. Onder T, Kara N, Cherry A, Sinha AU, Zhu N, Bernt KM, Cahan P, Marcarci BO, Unternaehrer J, Gupta PB, Lander ES, Armstrong SA, Daley GQ. Chromatin-modifying enzymes as modulators of reprogramming. Nature 2012; 483: 598-602.
58. Cattaneo P, Kunderfranco P, Greco C, Guffanti A, Stirparo GG, Rusconi F, Rizzi R, Di Pasquale E, Locatelli SL, Latronico MV, Bearzi C, Papait R, Condorelli G. DOT1L-mediated H3K79me2 modification critically regulates gene expression during cardiomyocyte differentiation. Cell Death Differ 2014; [Epub ahead of print].
59. Schulze J, Jackson J, Nakanishi S, Gardner JM, Hentrich T, Haug J, Johnston M, Jaspersen SL, Kobor MS, Shilatifard A. Linking cell cycle to histone modifications: SBF and H2B monoubiquitination machinery and cell-cycle regulation of H3K79 dimethylation. Mol Cell 2009; 35: 626-641.
60. De Vos D, Frederiks F, Terweij M, van Welsem T, Verzijlbergen KF, Iachina E, de Graaf EL, Altelaar AF, Oudgenoeg G, Heck AJ, Krijgsveld J, Bakker BM, van Leeuwen F. Progressive methylation of ageing histones by Dot1 functions as a timer. EMBO Rep 2011; 12: 956-962.
61. Kouskouti A, Talianidis I. Histone modifications defining active genes persist after transcriptional and mitotic inactivation. EMBO J 2005; 24: 347-357.
62. Kim S, Jung I, Lee H, Kang K, Kim M, Jeong K, Kwon CS, Han YM, Kim YS, Kim D, Lee D. Human Histone H3K79 Methyltransferase DOT1L Methyltransferase Binds Actively Transcribing RNA Polymerase II to Regulate Gene Expression. J Biol Chem 2012; 287: 39698-39709.
63. Suzuki M, Ito H, Aoki F. Effects of RNAi-Mediated Knockdown of Histone Methyltransferases on the Sex-Specific mRNA Expression of Imp in the Silkworm Bombyx mori. Int J Mol Sci 2014; 15: 6772-6792.
64. Shanower G, Muller M, Blanton JL, Honti V, Gyurkovics H, Schedl P. Characterization of the grappa gene, the Drosophila histone H3 lysine 79 methyltransferase. Genetics 2005; 169: 173-184.
65. Dottermusch-Heidel C, Gärtner SM, Tegeder I, Rathke C, Barckmann B, Bartkuhn M, Bhushan S, Steger K, Meinhardt A, Renkawitz-Pohl R. H3K79 methylation: a new conserved mark that accompanies H4 hyperacetylation prior to histone-to-protamine transition in Drosophila and rat. Biol Open 2014; 3: 444-452.
66. Dottermusch-Heidel C, Klaus ES, Gonzalez NH, Bhushan S, Meinhardt A, Bergmann M, Renkawitz-Pohl R, Rathke C, Steger K. H3K79 methylation directly precedes the histone-toprotamine transition in mammalian spermatids and is sensitive to bacterial infections. Andrology 2014; 2: 655-665.
67. Matsuura K, Fujimoto K, Das B, Fu L, Lu CD, Shi YB. Histone H3K79 methyltransferase Dot1L is directly activated by thyroid hormone receptor during Xenopus metamorphosis. Cell Biosci 2012; 2: 25.
68. Wen L, Fu L, Guo X, Chen Y, Shi YB. Histone methyltransferase Dot1L plays a role in postembryonic development in Xenopus tropicalis. FASEB J 2014; 385-393.
69. Tsai F, Keller G, Kuo FC, Weiss M, Chen J, Rosenblatt M, Alt FW, Orkin SH. An early hae matopoietic defect in mice lacking the transcription factor GATA-2. Nature 1994; 371: 221-6.
70. Back J, Dierich A, Bronn C, Kastner P, Chan S. PU.1 determines the self-renewal capacity of erythroid progenitor cells. Blood 2004; 130: 3615-3623.
71. Feng Y, Yang Y, Ortega MM, Copeland JN, Zhang M, Jacob JB, Fields TA, Vivian JL, Fields PE. Early mammalian erythropoiesis requires the Dot1L methyltransferase. Blood 2010; 116: 4483-4491.
72. Jo S, Granowicz EM, Maillard I, Thomas D and Hess JL. Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood 2011; 117: 4759-4768.
73. Nguyen A, He J, Taranova O, Zhang Y. Essential role of DOT1L in maintaining normal adult hematopoiesis. Cell Res 2011; 21: 1370-1373.
74. Wysocki R, Javaheri A, Allard S, Sha F, Côté J, Kron SJ. Role of Dot1-dependent histone H3 methylation in G1 and S phase DNA damage checkpoint functions of Rad9. Mol Cell Biol 2005; 25: 8430-8443.
75. San-Segundo P, Roeder GS. Role for the silencing protein Dot1 in meiotic checkpoint control. Mol Biol Cell 2000; 11: 3601-3615.
76. Botuyan M, Lee J, Ward IM, Kim JE, Thompson JR, Chen J, Mer G. Structural basis for the methylation state-specific recognition of histone H4-K20 by 53BP1 and Crb2 in DNA repair. Cell 2006; 127: 1361-1373.
77. FitzGerald J, Moureau S, Drogaris P, O'Connell E, Abshiru N, Verreault A, Thibault P, Grenon M, Lowndes NF. Regulation of the DNA damage response and gene expression by the Dot1L histone methyltransferase and the 53Bp1 tumour suppressor. PLoS One 2011; 6: e14714.
78. Wakeman T, Wang Q, Feng J, and Wang XF. Bat3 facilitates H3K79 dimethylation by DOT1L and promotes DNA damage-induced 53BP1 foci at G1/G2 cell-cycle phases. EMBO J 2012; 31: 2169-2181.
79. Huyen Y, Zgheib O, Ditullio RA Jr, Gorgoulis VG, Zacharatos P, Petty TJ, Sheston EA, Mellert HS, Stavridi ES, Halazonetis TD. Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks. Nature 2004; 432: 406-411.
80. Oksenych V, Zhovmer A, Ziani S, Mari PO, Eberova J, Nardo T, Stefanini M, Giglia-Mari G, Jean-Marc Egly JM, and Frédéric Coin F. Histone Methyltransferase DOT1L Drives Recovery of Gene Expression after a Genotoxic Attack. PLoS Genet 2013; 9: e1003611.
81. Biondi A, Cimino G, Pieters R, Pui CH. Biological and therapeutic aspects of infant leukemia. Blood 2000; 96: 24-33.
82. Ziemin-van der Poel S, McCabe NR, Gill HJ, Espinosa R 3rd, Patel Y, Harden A, Rubinelli P, Smith SD, LeBeau MM, Rowley JD, et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemia. Proc Natl Acad Sci U S A 1991; 88: 10735-9.
83. Dimartino J, Cleary ML. Mll rearrangements in haematological malignancies: lessons from clinical and biological studies. Br J Haematol. 1999; 106: 614-26.
84. Bitoun E, Oliver PL, Davies KE. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum Mol Genet 2007; 16: 92-106.
85. Krivtsov A, Feng Z, Lemieux ME, Faber J, Vempati S, Sinha AU, Xia X, Jesneck J, Bracken AP, Silverman LB, Kutok JL, Kung AL, Armstrong SA. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008; 14: 355-368.
86. Nguyen A, Taranova O, He J, Zhang Y. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood 2011; 117: 6912-6922.
87. Deshpande A, Chen L, Fazio M, Sinha AU, Bernt KM, Banka D, Dias S, Chang J, Olhava EJ, Daigle SR, Richon VM, Pollock RM, Armstrong SA. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood 2013; 121: 2533-2541.
88. Zeisig D, Bittner CB, Zeisig BB, Garcia-Cuellar MP, Hess JL, Slany RK. The eleven-nineteenleukemia protein ENL connects nuclear MLL fusion partners with chromatin. Oncogene 2005; 24: 5525-5532.
89. Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM, Su L, Xu G, Zhang Y. hDOT1L links histone methylation to leukemogenesis. Cell 2005; 121: 167-178.
90. Barry E, Corry GN, Rasmussen TP. Targeting DOT1L action and interactions in leukemia: the role of DOT1L in transformation and development. Expert Opin Ther Targets 2010; 14: 405-418.
91. Deshpande A, Bradner J, Armstrong SA. Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends Immunol 2012; 33: 563-570.
92. Buske C, Feuring-Buske M, Abramovich C, Spiekermann K, Eaves CJ, Coulombel L, Sauvageau G, Hogge DE, Humphries RK. Deregulated expression of HOXB4 enhances the primitive growth activity of human hematopoietic cells. Blood 2002; 100: 862-8.
93. Thorsteinsdottir U, Mamo A, Kroon E, Jerome L, Bijl J, Lawrence HJ, Humphries K, Sauvageau G. Overexpression of the myeloid leukemia associated Hoxa9 gene in bone marrow cells induces stem cell expansion. Blood 2002; 99: 121-129.
94. Milne T, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD, Hess JL. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 2002; 10: 1107-17.
95. Deshpande A, Deshpande A, Sinha AU, Chen L, Chang J, Cihan A, Fazio M, Chen CW, Zhu N, Koche R, Dzhekieva L, Ibáñez G, Dias S, Banka D, Krivtsov A, Luo M, Roeder RG, Bradner JE, Bernt KM, Armstrong SA. AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. Cancer Cell 2014; 26: 896-908.
96. Okada Y, Jiang Q, Lemieux M, Jeannotte L, Su L, Zhang Y. Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L. Nat Cell Bio 2006; 8: 1017-1024.
97. Chen L, Deshpande AJ, Banka D, Bernt KM, Dias S, Buske C, Olhava EJ, Daigle SR, Richon VM, Pollock RM, Armstrong SA. Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia 2013; 27: 812-822.
98. Shen C, Jo SY, Liao C, Hess JL, Nikolovska-Coleska Z. Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins. J Biol Chem 2013; 288: 30585-30596.
99. Kuntimaddi A, Achille NJ, Thorpe J, Lokken AA, Singh R, Hemenway CS, Adli M3, Zeleznik-Le NJ, Bushweller JH. Degree of Recruitment of DOT1L to MLL-AF9 Defines Level of H3K79 Di-and Tri-methylation on Target Genes and Transformation Potential. Cell Rep 2015; 11: 808-820.
100. Li Y, Wen H, Xi Y, Tanaka K, Wang H, Peng D, Ren Y, Jin Q, Dent SY, Li W, Li H, Shi X. AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation. Cell 2014; 159: 558-571.
101. Chen C, Koche RP, Sinha AU, Deshpande AJ, Zhu N, Eng R, Doench JG, Xu H, Chu SH, Qi J, Wang X, Delaney C, Bernt KM, Root DE, Hahn WC, Bradner JE, Armstrong SA. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLLrearranged leukemia. Nat Med 2015; 21: 335-343.
102. Kim W, Kim R, Park G, Park JW, Kim JE. Deficiency of H3K79 histone methyltransferase Dot1-like protein (DOT1L) inhibits cell proliferation. J Biol Chem 2012; 287: 5588-5599.
103. Kryczek I, Lin Y, Nagarsheth N, Peng D, Zhao L, Zhao E, Vatan L, Szeliga W, Dou Y, Owens S, Zgodzinski W, Majewski M, Wallner G, Fang J, Huang E, Zou W. IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity 2014; 40: 772-784.
104. Zhang L, Deng L, Chen F, Yao Y, Wu B, Wei L, Mo Q, Song Y. Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer. Oncotarget 2014; 5: 10665-10677.
105. Cho M, Park JH, Choi HJ, Park MK, Won HY, Park YJ, Lee CH, Oh SH, Song YS, Kim HS, Oh YH, Lee JY, Kong G. DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression. Nat Commun 2015; 6: 7821.
106. Guccione E, Martinato F, Finocchiaro G, Luzi L, Tizzoni L, Dall' Olio V, Zardo G, Nervi C, Bernard L, Amati B. Myc-binding-site recognition in the human genome is determined by chromatin context. Nat Cell Biol 2006; 8: 764-770.
107. Kim T, Barrera LO, Zheng M, Qu C, Singer MA, Richmond TA, Wu Y, Green RD, Ren B. A highresolution map of active promoters in the human genome. Nature 2005; 436: 876-880.
108. Gibbons G, Owens SR, Fearon ER, Nikolovska-Coleska Z. Regulation of Wnt signaling target gene expression by the histone methyltransferase DOT1L. ACS Chem Biol 2015; 10: 109-114.
109. Yu W, Chory EJ, Wernimont AK, Tempel W, Scopton A, Federation A, Marineau JJ, Qi J, Barsyte-Lovejoy D, Yi J, Marcellus R, Iacob RE, Engen JR, Griffin C, Aman A, Wienholds E, Li F, Pineda J, Estiu G, Shatseva T, Hajian T, Al-Awar R, Dick JE, Vedadi M, Brown PJ, Arrowsmith CH, Bradner JE, Schapira M. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat Commun 2012; 3: 1288.
110. Anglin J, Deng L, Yao Y, Cai G, Liu Z, Jiang H, Cheng G, Chen P, Dong S, Song Y. Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L. J Med Chem 2012; 55: 8066-8074.
111. Klaus C, Iwanowicz D, Johnston LD, Campbell CA, Smith JJ, Moyer MP, Copeland RA, Olhava EJ, Porter Scott M, Pollock RM, Daigle SR, Raimondi A. DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs and Hypomethylating Agents in MLL-Rearranged Leukemia Cells. J Pharmacol Exp Ther 2014; 350: 646-56.
112. Liu W, Deng L, Song Y, Redell M. DOT1L Inhibition Sensitizes MLL-Rearranged AML to Chemotherapy. PLoS One 2014; 9: e98270.
113. Yi J, Federation AJ, Qi J, Dhe-Paganon S, Hadler M, Xu X, St Pierre R, Varca AC, Wu L, Marineau JJ, Smith WB, Souza A, Chory EJ, Armstrong SA, Bradner JE. Structure-guided DOT1L probe optimization by label-free ligand displacement. ACS Chem Biol 2015; 10: 667-674.